Monopar Appoints Octávio Costa, MD, as Chief Medical Officer
12 juil. 2021 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO
24 juin 2021 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., June 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®
09 nov. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
06 août 2020 16h05 HE
|
Monopar Therapeutics Inc.
CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary...
Monopar Therapeutics Reports First Quarter 2020 Financial Results and Business Updates
07 mai 2020 09h00 HE
|
Monopar Therapeutics Inc.
CHICAGO, May 07, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics...
Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma
18 févr. 2020 09h00 HE
|
Monopar Therapeutics Inc.
CHICAGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ: MNPR) today announced it has been granted Orphan Drug Designation from the European Commission for its drug candidate...
Monopar Therapeutics Inc. Announces Closing of Initial Public Offering of Common Stock
23 déc. 2019 12h30 HE
|
Monopar Therapeutics Inc.
CHICAGO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced the closing of its initial public offering of 1,277,778 shares of common stock, including the underwriters’...
Monopar Therapeutics Inc. Announces Full Exercise of Over-Allotment by Underwriters
20 déc. 2019 16h46 HE
|
Monopar Therapeutics Inc.
CHICAGO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full...
Monopar Therapeutics Inc. Announces Pricing of Initial Public Offering
18 déc. 2019 19h52 HE
|
Monopar Therapeutics Inc.
CHICAGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced that it has priced an initial public offering of 1,111,112 shares of its common stock at $8.00 per share. The...